Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets.
(2018) Hepatobiliary & Pancreatic Diseases International — Vol. 17, n° 3, p. 192-197 (2018)
Files
document.pdf
Restricted Access - Adobe PDF
- 1004.18 KB
Details
- Authors
- Abstract
- Hepatic fibrosis is a pathological lesion, characterized by the progressive accumulation of extracellular matrix (ECM) in the perisinusoidal space and it is a major problem in chronic liver diseases. Phenotypic activation of hepatic stellate cells (HSC) plays a central role in the progression of hepatic fibrosis. Retardation of proliferation and clearance of activated HSCs from the injured liver is an appropriate therapeutic strategy for the resolution and treatment of hepatic fibrosis. Clearance of activated HSCs from the injured liver by autophagy inhibitors, proapoptotic agents and senescence inducers with the high affinity toward the activated HSCs may be the novel therapeutic strategy for the treatment of hepatic fibrosis in the near future.
- Affiliations
Citations
Ezhilarasan, D., Sokal, E., & Najimi, M. (2018). Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets. Hepatobiliary & Pancreatic Diseases International, 17(3), 192-197. https://doi.org/10.1016/j.hbpd.2018.04.003 (Original work published 2018)